Patents Issued in January 21, 2020
-
Patent number: 10538725Abstract: A bioprinter print head including a plurality of fluid dispensing segments arranged with respect to one another to form a three-dimensional lattice structure, each of the plurality of fluid dispensing segments having an inner member and an outer member, the outer member being positioned concentrically outward to the inner member, the inner member having a lumen and a fluid outlet port operable to deliver a biomaterial and the outer member operable to open or close the fluid outlet port. A method of bioprinting a three-dimensional biological structure, the method including simultaneously printing a three-dimensional matrix of biomaterial voxels within a support medium using a bioprinter print head assembly, removing the bioprinter head assembly from the support medium, and removing the support medium to form a self-supporting biological structure.Type: GrantFiled: November 3, 2015Date of Patent: January 21, 2020Assignee: AUTODESK, INC.Inventor: Joshua A. Natarajan
-
Patent number: 10538726Abstract: A system for microdialysis imaging and regional fluidic delivery and control includes a microdialysis imager including a imaging head having N pixels aligned in a pixel array for monitoring a living bio-object associated with the pixel array; and a fluidic module coupled to the microdialysis imager for delivering a fluidic substance to and collecting effluent from the living bio-object, including a fluidic network having a plurality of valves, a plurality of fluidic channels in fluidic communication with the plurality of valves and one or more pumps coupled to corresponding fluidic channels, and a microcontroller coupled to the fluidic network for individually controlling the plurality of valves and the one or more pumps of the fluidic network as so to operably and selectively deliver the fluidic substance to and continuously collect the effluent from the living bio-object responsive to the delivered fluidic substance via each pixel in real time.Type: GrantFiled: April 29, 2019Date of Patent: January 21, 2020Assignee: VANDERBILT UNIVERSITYInventors: John P. Wikswo, Ronald S. Reiserer, Kyle Hawkins
-
Patent number: 10538727Abstract: The present disclosure relates to hollow fiber tangential flow filters, including hollow fiber tangential flow depth filters, for various applications, including bioprocessing and pharmaceutical applications, systems employing such filters, and methods of filtration using the same.Type: GrantFiled: March 8, 2019Date of Patent: January 21, 2020Assignee: REPLIGEN CORPORATIONInventors: Michael Bransby, Derek Carroll
-
Patent number: 10538728Abstract: Provided is a bubble-jetting member, the tip section of which is not damaged even when high voltage is applied thereto. There can be provided a bubble jetting member comprising: a core that is formed of a conductive material; a shell part that is formed of an insulating material, includes an extended section that extends beyond the tip of the core, and is closely adhered at least partially to the core and covers the core; and a space that is formed between the extended section and the tip of the core and has a bubble-jetting port, wherein there is formed on the tip of the extended section a thick portion that is thicker than the rest of the extended section whereby the tip section is not damaged.Type: GrantFiled: November 4, 2015Date of Patent: January 21, 2020Assignee: Japan Science and Technology AgencyInventors: Yoko Yamanishi, Kazuki Takahashi, Shun Omi
-
Patent number: 10538729Abstract: There is provided a cell imaging control device, method, and a non-transitory computer readable recording medium recorded with a program capable of performing focus control more efficiently when imaging cells being cultured and improving the focus accuracy. There are included: an information acquisition unit 22 that acquires at least one of information regarding the maturity of cells being cultured or observation position information of the cells in a colony; a focus parameter determination unit 23 that determines a focus parameter based on at least one of the information regarding the maturity of the cells or the observation position information; and a focus control section 25 that performs focus control in an imaging device, which captures an image of the cells, based on the focus parameter.Type: GrantFiled: August 30, 2016Date of Patent: January 21, 2020Assignee: FUJIFILM CorporationInventor: Tsuyoshi Matsumoto
-
Patent number: 10538730Abstract: Reactors, systems and processes for the production of biomass by culturing microorganisms in aqueous liquid culture medium circulating inner loop reactor which utilize nonvertical pressure reduction zones are described. Recovery and processing of the culture microorganisms to obtain products, such as proteins or hydrocarbons is described.Type: GrantFiled: May 7, 2019Date of Patent: January 21, 2020Assignee: CALYSTA, INC.Inventors: Luan Thanh Nguyen, Arild Johannessen, Graham Ian Aylen, Joshua A. Silverman
-
Patent number: 10538731Abstract: Device for sorting living cells, comprising at least one support including a surface having adherence properties with respect to said type of living cells, actuators capable of making said surface vibrate at at least one given frequency and a controller for controlling the actuators such that the surface vibrates at a frequency causing the detachment of at least one type of living cells.Type: GrantFiled: February 18, 2016Date of Patent: January 21, 2020Assignee: Commissariat a L'Energie Atomique et aux Energies AlternativesInventors: Fabrice Casset, Arnaud Millet
-
Patent number: 10538732Abstract: A cell isolation method includes: a cell trapping step of allowing a test liquid to pass through a cell trapping filter which has a plurality of through-holes in the thickness direction, thereby trapping isolation target cells contained in the test liquid on one surface of the cell trapping filter; a gel embedding step of introducing a stimulus-responsive hydrogel onto the one surface of the cell trapping filter on which the cells have been trapped in the cell trapping step, thereby embedding the cells in the stimulus-responsive hydrogel; a gel hardening step of applying a stimulus to the stimulus-responsive hydrogel in which the cells are embedded, thereby hardening the stimulus-responsive hydrogel; and a detachment step of detaching the stimulus-responsive hydrogel that was hardened in the gel hardening step from the cell trapping filter.Type: GrantFiled: October 29, 2015Date of Patent: January 21, 2020Assignee: National University Corporation Tokyo University of Agriculture and TechnologyInventors: Tomoko Yoshino, Tsuyoshi Tanaka, Tadashi Matsunaga, Ryo Negishi, Hisashige Kanbara, Seita Nakamura
-
Patent number: 10538733Abstract: A cell, isolated nucleic acid, vector, isolated polypeptide, and method of treating a bacterial infection are provided. The cell includes a modified Acinetobacter baumannii cell having a mutation in an A. baumannii gene selected from a mutation that occurs when generating mutations in A. baumanni using transposon mutagenesis. The isolated nucleic acid includes a sequence expressing a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The vector includes the isolated nucleic acid. The isolated polypeptide includes a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The method of treating a bacterial infection includes administering to a subject an effective amount of an Acinetobacter baumannii composition including modified Acinetobacter baumannii cell.Type: GrantFiled: June 29, 2018Date of Patent: January 21, 2020Assignee: Vanderbilt UniversityInventors: Eric P. Skaar, M. Indriati Hood, Michael Noto
-
Patent number: 10538734Abstract: Disclosed is a composition for embedded three-dimensional microbial culture, the composition including nanofibrillar cellulose and at least one nutrient source. Also disclosed is a method for the manufacture of a composition for embedded three-dimensional microbial culture, the method including the steps of providing nanofibrillar cellulose, mixing the nanofibrillar cellulose with water and at least one nutrient source and optional additives to obtain a mixture, and optionally drying the mixture.Type: GrantFiled: December 18, 2012Date of Patent: January 21, 2020Assignee: UPM-KYMMENE CORPORATIONInventors: Marko Lauraeus, Antti Laukkanen
-
Patent number: 10538735Abstract: A composition for fermentation or microbial culture of gram-positive bacteria, includes fibril cellulose and at least one nutrient source including at least one carbon source, at least one nitrogen source, at least one phosphorus source, at least one mineral source and at least one trace element source.Type: GrantFiled: December 18, 2012Date of Patent: January 21, 2020Assignee: UPM-KYMMENE CORPORATIONInventors: Marko Lauraeus, Antti Laukkanen
-
Patent number: 10538736Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: November 30, 2016Date of Patent: January 21, 2020Assignee: Histogen, Inc.Inventors: Gail K. Naughton, Francis C. Zeigler, Mark Baumgartner, Kyle Nickey
-
Patent number: 10538737Abstract: The invention relates to a large scale process for the in vitro production of a cell culture of pomegranate cells, to a product prepared from such cells and to a composition comprising a complex of pholyphenols, including punicalagin, 1,2,3,4,6-pentagalloyl glucose (PGG) or both.Type: GrantFiled: January 5, 2015Date of Patent: January 21, 2020Assignee: BIO HARVEST LTD.Inventors: Yoheved Hagay, Malkit Azachi, Rivka Yatuv
-
Patent number: 10538738Abstract: Applications in transfusion medicine requiring platelets, and hematopoietic stem-cell transplantations require either platelets or enhancement of in vivo platelet biogenesis. Gene therapy applications of hematopoietic stem and progenitor cells (HSPCs) require effective and specific modification of HSPCs by DNA, RNA or other biological molecules. Here we disclose methods for the generation, and modification of megakaryocytic microparticles (MkMPs) or microvesicles, that can be used in the aforementioned transfusion and transplantation medicine applications and in gene therapy applications involving hematopoietic stem cells. The biological effects of modified or unmodified MkMPs have never been previously disclosed and thus, this invention claims all biological applications of MkMPs in in vivo therapeutic applications or ex vivo applications to produce various cells and cell parts, modify various target cells or deliver molecules including drugs to HSPCs and related cells.Type: GrantFiled: May 18, 2015Date of Patent: January 21, 2020Inventors: Eleftherios Papoutsakis, Chen-Yuan Kao, Jinlin Jiang
-
Patent number: 10538739Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.Type: GrantFiled: October 28, 2016Date of Patent: January 21, 2020Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPOREInventors: Dario Campana, Yu-Hsiang Chang
-
Patent number: 10538740Abstract: An object of the present invention is to provide a novel method for sorting cardiomyocytes. Another object of the present invention is to provide a method for producing high-purity cardiomyocytes and a kit used therefor. The present invention provides a method for sorting cardiomyocytes, comprising a step of introducing miRNA-responsive mRNA into a cell group, wherein the miRNA-responsive mRNA consists of a sequence comprising the following (i) and (ii): (i) a nucleic acid specifically recognized by miRNA specifically expressed in cardiomyocytes, and (ii) a nucleic acid corresponding to the coding region of a gene, wherein translation of (ii) the nucleic acid corresponding to the coding region of a gene into protein is regulated by the nucleic acid sequence in (i) above, thereby achieving the aforementioned objects.Type: GrantFiled: March 20, 2015Date of Patent: January 21, 2020Assignee: Kyoto UniversityInventors: Yoshinori Yoshida, Hirohide Saito, Kenji Miki, Kei Endo, Seiya Takahashi
-
Patent number: 10538741Abstract: Novel adult liver progenitor cells (called H2Stem Cells) have been have been characterized on the basis of a series of biological activities and markers. Methods for producing H2Stem Cells allow providing such cells in the form of adherent cells and three-dimensional cell clusters in suspension that can be differentiated into cells having strong liver-specific activities and/or that can be used for treating liver diseases or for evaluating the efficacy, the metabolism, and/or toxicity of a compound.Type: GrantFiled: August 28, 2015Date of Patent: January 21, 2020Assignee: Promethera Biosciences S.A./N.V.Inventors: Etienne Sokal, Sarah Snykers, Tuba Baran, Kris Gellynck, Luca Falciola
-
Patent number: 10538742Abstract: This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.Type: GrantFiled: November 12, 2005Date of Patent: January 21, 2020Assignee: Cambridge Enterprise LimitedInventor: Toru Kondo
-
Patent number: 10538743Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: GrantFiled: June 23, 2016Date of Patent: January 21, 2020Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
-
Patent number: 10538744Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.Type: GrantFiled: March 7, 2017Date of Patent: January 21, 2020Inventor: Per Sonne Holm
-
Patent number: 10538745Abstract: A recombinant virus is obtained by mutating a codon that encodes a tyrosine residue at position 385 of NP protein in the genome of influenza A virus to a codon of phenylalanine residue. The virus WSN-Y385F is a temperature-sensitive virus that can normally replicate and survive at 37° C., and cannot normally replicate and cannot survive at 33° C. Phosphorylation of a NP protein of influenza A virus can be inhibited by mutating an amino acid residue at position 385 from N terminal of the NP protein of influenza A virus, from a tyrosine to a phenylalanine. The recombinant virus can be used in analyzing mechanisms of infection by influenza virus, and in connection with methods of prevention and treatment of infection by influenza virus.Type: GrantFiled: January 22, 2017Date of Patent: January 21, 2020Assignee: Institute of Microbiology, Chinese Academy of SciencesInventors: Wenjun Liu, Weinan Zheng, Jing Li
-
Patent number: 10538746Abstract: The disclosure relates to polypeptides having carboxylic acid reductase (CAR) activity, including enzymes that catalyse the irreversible reduction of carboxylic acids, such as pimelic acid and adipic acid, to their respective semialdehydes. The enzymes have been engineered to have higher activity over a corresponding wild type enzyme. Provided herein are novel polypeptides and uses thereof related to the same.Type: GrantFiled: March 16, 2017Date of Patent: January 21, 2020Assignee: INVISTA North America S.Ã r.l.Inventors: Alexander Brett Foster, Adriana Leonora Botes
-
Patent number: 10538747Abstract: Provided are a novel separated polypeptide having transaminase activity, a polynucleotide encoding the polypeptide, a microorganism including the polynucleotide, and a method of deaminating an amino compound by using the polypeptide or the microorganism.Type: GrantFiled: June 3, 2016Date of Patent: January 21, 2020Assignee: CJ CHEILJEDANG CORPORATIONInventors: Jae Hun Lee, Young Lyeol Yang, In Seok Oh
-
Patent number: 10538749Abstract: The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having two site mutations, methods of production, and methods of use to effectively degrade cylcosarin (GF) (cyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA.Type: GrantFiled: January 19, 2018Date of Patent: January 21, 2020Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Steven P Harvey, Melissa M Dixon, Mark A Guelta
-
Patent number: 10538750Abstract: This invention relates to reagents and methods for increasing specificity and efficiency of genome editing by CRISPR associated (Cas) protein systems, more particularly by Cas:guide RNA complexes, by blocking off-target nucleic acids from cleavage by Cas:guide RNA complexes.Type: GrantFiled: February 24, 2017Date of Patent: January 21, 2020Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Chong Wing Yung, Andrew Kennedy
-
Patent number: 10538751Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: GrantFiled: June 4, 2014Date of Patent: January 21, 2020Assignee: NOVOZYMES A/SInventor: Carsten Andersen
-
Patent number: 10538752Abstract: The present disclosure relates to isolated polypeptides having alpha-amylase activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides, and method of using polypeptides, including in ethanol production processes.Type: GrantFiled: August 17, 2017Date of Patent: January 21, 2020Assignee: NOVOZYMES A/SInventors: Guillermo Coward-Kelly, Shiro Fukuyama, Noriko Tsutsumi, Keiichi Ayabe
-
Patent number: 10538753Abstract: Disclosed herein are methods of making multifunctional microbial cellulases. The engineered multifunctional microbial cellulases disclosed herein exhibit improved activity over native cellulases.Type: GrantFiled: March 6, 2018Date of Patent: January 21, 2020Assignee: Alliance for Sustainably Enegry, LLCInventors: Roman Brunecky, Venkataramanan Subramanian, Stephen Robert Decker, Michael E. Himmel
-
Patent number: 10538754Abstract: The present invention is directed to methods for the production of thrombin from a source of prothrombin using a given BaSO4 reagent as an adsorbent of prothrombin as well as methods for evaluating the suitability of a given BaSO4 reagent for use in preparation of thrombin. In at least one embodiment, the method includes contacting a sample of the given BaSO4 reagent with a source of prothrombin to obtain BaSO4-adsorbed prothrombin, and subsequently evaluating the pro-coagulant activity of the BaSO4-adsorbed prothrombin. In another embodiment, the method includes the step of evaluating relative to the pro-coagulant activity of normal mammalian plasma.Type: GrantFiled: February 6, 2015Date of Patent: January 21, 2020Assignees: Omrix Biopharmaceuticals Ltd.Inventors: Lior Weissman, Dana Sella, Israel Nur, Caixia Jiang, Baochang An
-
Patent number: 10538755Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.Type: GrantFiled: April 11, 2017Date of Patent: January 21, 2020Assignee: OPKO Biologics Ltd.Inventors: Udi Eyal Fima, Gili Hart
-
Patent number: 10538756Abstract: A system and method for reversibly controlling clustering of proteins around an engineered multivalent nucleus is disclosed. The system and method utilize clustering, which may be controlled by light activation or deactivation. The system and method enable the spatiotemporal control of protein supramolecular assemblies, including liquid-like droplets under some conditions, and solid-like gels under other conditions. The system and method can be utilized for segregating or locally concentrating desired proteins and/or RNA in cells or cell lysate, which may be useful for protein purification purposes, or for assembling single or multiple membraneless bodies within specific sub-regions of the cells. These synthetically assembled bodies may recruit both transgenic and endogenic proteins and other biomolecules, thus can be linked to affect and even trigger a plethora of cellular processes, including both physiological and pathological (e.g., protein aggregation) processes.Type: GrantFiled: June 9, 2017Date of Patent: January 21, 2020Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Cliff Brangwynne, Dan Bracha
-
Patent number: 10538757Abstract: Embodiments of the present disclosure provide for nanozymes that can include a therapeutic agent, methods of making nanozymes, methods of using nanozymes, and the like. In some embodiments, the nanozymes can include a shell that can surround a hollow core that can be configured to receive a compound and the shell can include a recognition moiety and an enzyme.Type: GrantFiled: February 12, 2016Date of Patent: January 21, 2020Assignee: University of Florida Research Foundation, Inc.Inventors: Yunwei Charles Cao, Chen Liu
-
Patent number: 10538758Abstract: Provided herein are methods and compositions for the capture of nucleic acids, for example by using a nucleic acid-guided nuclease-based system.Type: GrantFiled: August 18, 2016Date of Patent: January 21, 2020Assignee: Arc Bio, LLCInventors: Stephane B. Gourguechon, Eric Harness, David Sinclair, Meredith L. Carpenter
-
Patent number: 10538759Abstract: The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.Type: GrantFiled: November 20, 2017Date of Patent: January 21, 2020Assignee: Illumina, Inc.Inventors: John R. Stuelpnagel, David L. Barker, Jorge Velarde, Steven M. Barnard, Michael Graige
-
Patent number: 10538760Abstract: This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes.Type: GrantFiled: December 11, 2015Date of Patent: January 21, 2020Assignee: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes
-
Patent number: 10538761Abstract: Provided herein, inter alia, are double stranded oligonucleotide molecules and methods of making the molecules. The double stranded oligonucleotide molecules include a first oligonucleotide strand comprising a first nucleic acid sequence bound to a second nucleic acid sequence through a first spacer, wherein said second nucleic acid sequence is bound to a third nucleic acid sequence through a second spacer and a second oligonucleotide strand comprising a fourth nucleic acid sequence bound to a fifth nucleic acid sequence through a third spacer, wherein said fifth nucleic acid sequence is bound to a sixth nucleic acid sequence through a fourth spacer, wherein the second nucleic acid sequence and the fifth nucleic acid sequence are hybridized to form a double stranded nucleic acid core of said double stranded oligonucleotide.Type: GrantFiled: July 13, 2016Date of Patent: January 21, 2020Assignee: City of HopeInventor: Piotr Swiderski
-
Patent number: 10538762Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).Type: GrantFiled: October 8, 2015Date of Patent: January 21, 2020Assignee: The Board of Regents of the University of Texas SystemInventors: David Corey, Jiaxin Hu
-
Patent number: 10538763Abstract: The present disclosure pertains generally to double-stranded small interfering RNAs that modulate gene expression for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure provides double-stranded small interfering RNAs that modulate DUX4 gene expression. In certain embodiments, the present disclosure provides methods of inhibiting DUX4 gene expression by contacting a cell with double-stranded small interfering RNAs.Type: GrantFiled: January 15, 2016Date of Patent: January 21, 2020Assignees: Ionis Pharmaceuticals, Inc., Fred Hutchinson Cancer Research CenterInventors: Frank Rigo, Stephen J. Tapscott
-
Patent number: 10538764Abstract: Disclosed herein are methods, compositions, polynucleic acid polymers, assays, and kits for inducing processing of a partially processed mRNA transcript to remove a retained intron to produce a fully processed mRNA transcript that encodes a full-length functional form of a protein. Also described herein are methods and compositions for treating a disease or condition characterized by impaired production of a full-length functional form of a protein or for treating a disease or condition characterized by a defective splicing in a subject.Type: GrantFiled: June 12, 2017Date of Patent: January 21, 2020Assignee: University of SouthamptonInventors: Igor Vorechovsky, Jana Kralovicova
-
Patent number: 10538765Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: GrantFiled: December 7, 2017Date of Patent: January 21, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Patent number: 10538766Abstract: This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.Type: GrantFiled: August 21, 2018Date of Patent: January 21, 2020Assignees: Emory University, Georgia Tech Research CorporationInventors: Hanjoong Jo, Dongju Son, Wakako Takabe, Sandeep Kumar, Hhaiwei Qiu, Chanwoo Kim
-
Patent number: 10538767Abstract: Treatment of tumors, especially breast cancer or glioblastoma tumors, by silencing RAB27A and/or TRAF3IP2, compositions and methods for same.Type: GrantFiled: November 26, 2018Date of Patent: January 21, 2020Assignee: The Administrators of the Tulane Educational FundInventors: Eckhard Alt, Reza Izadpanah
-
Patent number: 10538768Abstract: The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2?-fluoro, 2?-O-methoxy and/or 2?-O-methyl modified nucleotides. The selected regions are preferably the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1, specific regions of the TGF-beta1 nucleic acid sequence of SEQ ID NO. 149, or specific regions of the TGF-beta3 nucleic acid sequence of SEQ ID No. 267. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and/or treatment of a malignant and/or benign tumor, an immunologic disease, fibrosis, glaucoma, etc.Type: GrantFiled: January 29, 2018Date of Patent: January 21, 2020Assignee: ISARNA THERAPEUTICS GMBHInventors: Frank Jaschinski, Michel Janicot, Eugen Uhlmann
-
Patent number: 10538769Abstract: Compositions and methods for treating hypertension in a subject are provided, including administering an antisense oligomer effective to reduce expression of cytochrome P450 3A5 (CYP3A5) enzyme. The antisense oligomer includes phosphorodiamidate morpholino oligonucleotide (PMO), phosphorothioate 2?-O-methyl oligoribonucleotides (PSO), locked nucleic acid nucleotide, locked nucleic acid analog nucleotide, or another modified oligonucleotide backbone or nuclease-resistant backbone. The antisense oligomer is administered transdermally, subcutaneously, or orally, and optionally with a pharmaceutically acceptable carrier. In one embodiment, the antisense oligomer is an oligomer that is antisense to mRNAs that encode CYP3A5, for instance targeted at the AUG start site of the mRNAs that encode CYP3A5 or at a G4 structure within CYP3A5.Type: GrantFiled: September 2, 2016Date of Patent: January 21, 2020Assignee: Oregon State UniversityInventors: Patrick L. Iversen, Andrew J. Annalora
-
Patent number: 10538770Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules such as chikungunya viral proteins, such as chikungunya envelope protein E1.Type: GrantFiled: September 21, 2017Date of Patent: January 21, 2020Assignee: Base Pair Biotechnologies, Inc.Inventor: George W. Jackson
-
Patent number: 10538771Abstract: Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorganism; and performing an assay to detect the second aptamer, wherein detecting the second aptamer indicates that the microorganism is present in the sample, and wherein not detecting the second aptamer indicates that the microorganism is absent from the sample.Type: GrantFiled: August 31, 2018Date of Patent: January 21, 2020Assignee: SomaLogic, Inc.Inventors: Urs A. Ochsner, Nebojsa Janjic
-
Patent number: 10538772Abstract: The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising the nucleic acid molecules, polypeptides encoded by the nucleic acid molecules, compositions comprising the nucleic acid molecules or polypeptides, and methods of making and uses thereof.Type: GrantFiled: December 7, 2016Date of Patent: January 21, 2020Inventors: Kirk E. Apt, Leslie Richter, David Simpson, Ross Zirkle
-
Patent number: 10538773Abstract: Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNASep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Mutant EF-Sep proteins are disclosed that bind Sep-tRNASep and protect Sep-tRNASep from deacylation. In a preferred embodiment the nucleic acids are on vectors and are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.Type: GrantFiled: February 22, 2017Date of Patent: January 21, 2020Assignee: Yale UniversityInventors: Hee-Sung Park, Dieter Soll
-
Patent number: 10538774Abstract: Methods and means are provided to modify in a targeted manner the genome of a plant in close proximity to an existing elite event using a double stranded DNA break inducing enzyme. Also provided are plants, in particular cotton plants showing tolerance to a field dose of at least 1X of at least one HPPD inhibitor, and methods for making such plants.Type: GrantFiled: August 14, 2012Date of Patent: January 21, 2020Assignee: BASF AGRICULTURAL SOLUTIONS SEED, US LLCInventor: Kathleen D'Halluin
-
Patent number: 10538775Abstract: The present invention discloses polynucleotide sequences that can be used to regulate gene expression in plants. Terminator sequences from Sorghum bicolor that are functional in plants are disclosed.Type: GrantFiled: July 23, 2012Date of Patent: January 21, 2020Assignee: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: Shane E Abbitt, Rudolf Jung